UNSPSC 51284601: Biapenem

This classification denotes a beta-lactam antibiotic with the molecular formula C15H18N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YR5U3L9ZH1, chemically known as 6-(((4r,5s,6s)-2-carboxy-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)thio)-6,7-dihydro-5h-pyrazolo(1,2-a)-s-triazol-4-ium hydroxide, inner salt but generally known as biapenem, which bears US NIH Compound Identifier 71339.

UNSPSC 51284601 Biapenem, a Commodity code, shows no recent state and local procurement activity aligned with its nominal scope. The four opportunities tagged under this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives and direct-to-manufacturer prescriptions, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which relate to biapenem, a beta-lactam antibiotic. The mismatch suggests either miscoding at the source or that biapenem procurement, if it occurs at state and local levels, remains below the visibility threshold of posted opportunities.

The opportunities present do reveal broader patterns in state and local pharmaceutical and medical supply procurement. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). Recent solicitations have targeted naloxone procurement via IFB with quarterly delivery cycles, exploratory RFI activity for direct manufacturer engagement, medical supply IFB with SLBE set-asides and firm pricing, and multistate RFP activity for generic pharmaceuticals with wholesaler distribution through established channels. Absent specific recent activity under the biapenem code itself, firms pursuing pharmaceutical manufacturing or distribution to state and local markets should monitor the broader prescription-drug and medical-supply procurement stream through cooperative purchasing vehicles and state health department channels rather than this code.